JP2018537529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537529A5 JP2018537529A5 JP2018544771A JP2018544771A JP2018537529A5 JP 2018537529 A5 JP2018537529 A5 JP 2018537529A5 JP 2018544771 A JP2018544771 A JP 2018544771A JP 2018544771 A JP2018544771 A JP 2018544771A JP 2018537529 A5 JP2018537529 A5 JP 2018537529A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- position corresponding
- peptide
- par2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000001014 amino acid Nutrition 0.000 claims 73
- 108090000765 processed proteins & peptides Proteins 0.000 claims 42
- 150000001413 amino acids Chemical class 0.000 claims 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 claims 24
- 102000050100 human F2RL1 Human genes 0.000 claims 24
- 102000032628 PAR-2 Receptor Human genes 0.000 claims 19
- 108010070503 PAR-2 Receptor Proteins 0.000 claims 19
- 230000035772 mutation Effects 0.000 claims 17
- 229910052698 phosphorus Inorganic materials 0.000 claims 14
- 125000000539 amino acid group Chemical group 0.000 claims 12
- 230000002209 hydrophobic effect Effects 0.000 claims 12
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 10
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 9
- 150000008574 D-amino acids Chemical class 0.000 claims 9
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 8
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 8
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 5
- 239000004472 Lysine Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 229960002591 hydroxyproline Drugs 0.000 claims 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 5
- 108091035707 Consensus sequence Proteins 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 4
- 229960002173 citrulline Drugs 0.000 claims 4
- 235000013477 citrulline Nutrition 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 125000003473 lipid group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- -1 tridecanoyl Chemical group 0.000 claims 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 claims 2
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 claims 2
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 206010028537 myelofibrosis Diseases 0.000 claims 2
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 150000003431 steroids Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- CNOKQOBEMGIIAH-JYAZKYGWSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O CNOKQOBEMGIIAH-JYAZKYGWSA-N 0.000 claims 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 1
- 206010021531 Impetigo Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 229940118430 Protease-activated receptor-2 antagonist Drugs 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 230000006229 amino acid addition Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000003910 behenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000003185 calcium uptake Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical group C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
- 229960003964 deoxycholic acid Drugs 0.000 claims 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 108091005995 glycated hemoglobin Proteins 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000000403 lignoceroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims 1
- 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 210000002752 melanocyte Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000004848 polyfunctional curative Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 239000003229 sclerosing agent Substances 0.000 claims 1
- 108010014211 seryl-leucyl-isoleucyl-glycyl-arginyl-leucine Proteins 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022145694A JP2022179508A (ja) | 2015-11-13 | 2022-09-13 | プロテアーゼ活性化受容体２のモジュレーター |
| JP2024207359A JP2025036429A (ja) | 2015-11-13 | 2024-11-28 | プロテアーゼ活性化受容体２のモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255334P | 2015-11-13 | 2015-11-13 | |
| US62/255,334 | 2015-11-13 | ||
| PCT/US2016/061489 WO2017083618A1 (en) | 2015-11-13 | 2016-11-11 | Protease-activated receptor-2 modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022145694A Division JP2022179508A (ja) | 2015-11-13 | 2022-09-13 | プロテアーゼ活性化受容体２のモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537529A JP2018537529A (ja) | 2018-12-20 |
| JP2018537529A5 true JP2018537529A5 (https=) | 2019-12-26 |
| JP7621728B2 JP7621728B2 (ja) | 2025-01-27 |
Family
ID=57394682
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544771A Active JP7621728B2 (ja) | 2015-11-13 | 2016-11-11 | プロテアーゼ活性化受容体２のモジュレーター |
| JP2022145694A Pending JP2022179508A (ja) | 2015-11-13 | 2022-09-13 | プロテアーゼ活性化受容体２のモジュレーター |
| JP2024207359A Pending JP2025036429A (ja) | 2015-11-13 | 2024-11-28 | プロテアーゼ活性化受容体２のモジュレーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022145694A Pending JP2022179508A (ja) | 2015-11-13 | 2022-09-13 | プロテアーゼ活性化受容体２のモジュレーター |
| JP2024207359A Pending JP2025036429A (ja) | 2015-11-13 | 2024-11-28 | プロテアーゼ活性化受容体２のモジュレーター |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11091533B2 (https=) |
| EP (1) | EP3374386B1 (https=) |
| JP (3) | JP7621728B2 (https=) |
| AU (1) | AU2016354478B2 (https=) |
| ES (1) | ES2984663T3 (https=) |
| WO (1) | WO2017083618A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160000791A1 (en) | 2014-07-07 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Par1 modulation to alter myelination |
| WO2017083618A1 (en) | 2015-11-13 | 2017-05-18 | Oasis Pharmaceuticals, LLC | Protease-activated receptor-2 modulators |
| WO2017194716A1 (en) * | 2016-05-12 | 2017-11-16 | Astrazeneca Ab | Inhibitors of protease-activated receptor-2 |
| AU2019310039A1 (en) * | 2018-07-23 | 2021-02-18 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
| AU2020271894A1 (en) | 2019-04-11 | 2021-12-02 | Enclear Therapies, Inc. | Methods of amelioration of cerebrospinal fluid and devices and systems therefor |
| EP4090372A4 (en) * | 2020-01-14 | 2023-10-18 | Mayo Foundation for Medical Education and Research | Targeting par1 and par2 to regulate lipid and cholesterol abundance |
| US12329930B2 (en) | 2020-09-29 | 2025-06-17 | Enclear Therapies, Inc. | Subarachnoid fluid management method and system |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266930B1 (en) | 1993-03-05 | 2016-02-23 | Epimmune Inc. | Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions |
| US5716789A (en) * | 1993-07-26 | 1998-02-10 | Cor Therapeutics, Inc. | Method to determine ligands, agonist and antagonist of C140 receptor |
| EP0835928A1 (en) | 1996-10-11 | 1998-04-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | Helicobacter pylori live vaccine |
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| US6815200B1 (en) | 1998-02-17 | 2004-11-09 | The Uab Research Foundation | Modified adenovirus containing a fiber replacement protein |
| DE69942176D1 (de) | 1998-04-07 | 2010-05-06 | Medimmune Llc | Choline-bindende proteine derivate aus pneumokoken als impfstoff |
| US6562958B1 (en) | 1998-06-09 | 2003-05-13 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics |
| WO2000034469A1 (en) | 1998-12-11 | 2000-06-15 | The Research Foundation Of State University Of New York At Albany | Compositions and methods for altering cell migration |
| US6703491B1 (en) | 1999-03-17 | 2004-03-09 | Exelixis, Inc. | Drosophila sequences |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
| EP2348047A1 (en) | 2000-04-21 | 2011-07-27 | New England Medical Center | G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
| US6773893B1 (en) | 2000-04-28 | 2004-08-10 | The Trustees Of Columbia University In The City Of New York | Human ABC1 promoter and assays based thereon |
| US7834146B2 (en) | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
| EP1197755A1 (en) | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
| US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| CA2492938C (en) | 2002-08-02 | 2012-05-22 | Joseph H. Coggin, Jr. | Cancer vaccines containing epitopes of oncofetal antigen |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US7189691B2 (en) | 2004-04-01 | 2007-03-13 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating leukemia |
| US20070207209A1 (en) | 2004-08-27 | 2007-09-06 | Murphy Christopher J | Trophic factor combinations for nervous system treatment |
| US7319142B1 (en) | 2004-08-31 | 2008-01-15 | Monsanto Technology Llc | Nucleotide and amino acid sequences from Xenorhabdus and uses thereof |
| JP2008519039A (ja) | 2004-11-04 | 2008-06-05 | ニュー イングランド メデカル センター ホスピタルズ インク | Ｇタンパク質共役型受容体アゴニストおよびアンタゴニストならびに使用方法 |
| US8088976B2 (en) | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
| WO2007061850A2 (en) | 2005-11-17 | 2007-05-31 | Massachusetts Institute Of Technology | Methods and systems for generating and evaluating peptides |
| US8575070B2 (en) | 2006-02-20 | 2013-11-05 | Phylogica Limited | Methods of constructing and screening libraries of peptide structures |
| AU2007284651B2 (en) | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
| TW201531484A (zh) | 2007-05-21 | 2015-08-16 | Alder Biopharmaceuticals Inc | 抗ＴＮＦ-α之抗體及其用途 |
| JP4400668B2 (ja) | 2007-11-01 | 2010-01-20 | 株式会社豊田中央研究所 | 微小物体が固定化された固相体の製造方法及びその利用 |
| US9029636B2 (en) | 2008-02-05 | 2015-05-12 | Monsanto Technology Llc | Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits |
| WO2010021822A2 (en) * | 2008-07-30 | 2010-02-25 | The Regents Of The University Of California | Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites |
| JP2012507524A (ja) | 2008-11-04 | 2012-03-29 | アンカー セラピューティクス，インコーポレイテッド | Ｃｘｃｒ４受容体化合物 |
| WO2010053545A2 (en) | 2008-11-04 | 2010-05-14 | Anchor Therapeutics, Inc. | Apj receptor compounds |
| US20100184684A1 (en) | 2009-01-06 | 2010-07-22 | C3 Jian, Inc. | Antibacterial and antifungal peptides |
| US9012723B2 (en) | 2009-01-16 | 2015-04-21 | Monsanto Technology Llc | Isolated novel acid and protein molecules from soy and methods of using those molecules to generate transgene plants with enhanced agronomic traits |
| WO2010091294A2 (en) | 2009-02-05 | 2010-08-12 | The Regents Of The University Of California | New targeted antimicrobial moieties |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| EP3351641A1 (en) | 2011-04-08 | 2018-07-25 | Tufts Medical Center, Inc. | Pepducin design and use |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9091651B2 (en) * | 2011-12-21 | 2015-07-28 | Integrated Diagnostics, Inc. | Selected reaction monitoring assays |
| WO2017083618A1 (en) | 2015-11-13 | 2017-05-18 | Oasis Pharmaceuticals, LLC | Protease-activated receptor-2 modulators |
-
2016
- 2016-11-11 WO PCT/US2016/061489 patent/WO2017083618A1/en not_active Ceased
- 2016-11-11 EP EP16801353.0A patent/EP3374386B1/en active Active
- 2016-11-11 JP JP2018544771A patent/JP7621728B2/ja active Active
- 2016-11-11 US US15/349,364 patent/US11091533B2/en active Active
- 2016-11-11 ES ES16801353T patent/ES2984663T3/es active Active
- 2016-11-11 AU AU2016354478A patent/AU2016354478B2/en active Active
-
2020
- 2020-07-10 US US16/926,304 patent/US11732027B2/en active Active
-
2022
- 2022-09-13 JP JP2022145694A patent/JP2022179508A/ja active Pending
-
2024
- 2024-11-28 JP JP2024207359A patent/JP2025036429A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537529A5 (https=) | ||
| ES2984663T3 (es) | Moduladores del receptor 2 activados por proteasa | |
| US9683019B2 (en) | Cyclic polypeptides for the treatment of heart failure | |
| CN114341161A (zh) | 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途 | |
| NZ597554A (en) | Selective glucagon-like-peptide-2 (glp-2) analogues | |
| JP2017530090A5 (https=) | ||
| JP2010508305A5 (https=) | ||
| US20230287051A1 (en) | Inhibitors of complement factor c3 and their medical uses | |
| CA3195315A1 (en) | Compositions and methods for selective depletion of target molecules | |
| JP2014511866A5 (https=) | ||
| JP2018519254A5 (https=) | ||
| US8003610B2 (en) | Bradykinin B2 receptor antagonist peptide from amphibian skin | |
| EP3177309A1 (en) | Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same | |
| JP5698977B2 (ja) | メタスチン誘導体およびその用途 | |
| CN116199744B (zh) | 一种结合fgfr2受体的多肽及其用途 | |
| Badgery-Parker et al. | Receptor binding profile of neuropeptide γ and its fragments: Comparison with the nonmammalian peptides carassin and ranakinin at three mammalian tachykinin receptors | |
| JP2002534996A5 (https=) | ||
| JPWO2023282281A5 (https=) | ||
| TW202042836A (zh) | 血球凝集素結合肽 | |
| EP4611787A1 (en) | Ccr2 inhibitors and methods of use | |
| Roosenburg et al. | Synthesis and characterization of new radiolabeled CCK8 analogues for targeting CCK2 receptor expressing tumors |